A research-use-only label does not change what a peptide is when it is meant for dogs. FDA decides whether a product is a drug by its intended use, and the research exemption in 21 CFR 511.1(a) covers only tests in vitro or in animals used only for laboratory research, which a client-owned dog is not. A real study that gives the peptide to client-owned dogs runs under an investigational new animal drug exemption (INAD) in 21 CFR 511.1(b): an investigational label, a notice to FDA before the product ships, qualified investigators, complete records kept two years, a monitor, prompt reporting of hazards, and no claim that the product is safe or effective. If the results are meant for FDA, the study also follows Guidance #85 (VICH GL9): owner consent before the dog takes part, a protocol signed by sponsor and investigator, and an audit trail.
Why the label does not settle it
21 CFR 201.128 defines intended use as "the objective intent of the persons legally responsible for the labeling." Labeling claims, advertising and statements can show it. So can circumstances in which the product is, with the seller's knowledge, "offered or used for a purpose for which it is neither labeled nor advertised." FDA's page on unapproved animal drugs (updated January 7, 2025) says "The intended use of a product determines if it's a drug" and "If a drug is intended for use in animals, it's almost certain to be a new animal drug." A company may market one for the uses on its label once FDA has approved, conditionally approved or indexed it; the page says marketing an unapproved one is illegal.
The veterinarian's route does not reach it either. 21 CFR 530.1 limits extra-label use to an "approved new animal drug or approved new human drug," used by or on the order of a licensed veterinarian within a valid veterinary-client-patient relationship. A product with no approval is outside Part 530. None of these rules names peptides; each applies to a product by what it is for.
What the design changes
| Design | INAD under 511.1 | Conduct standard | What the data can carry |
|---|---|---|---|
| Observational: dogs already given the product; the study supplies and assigns nothing | Not triggered by the study, since nothing ships for investigation; the product's status is unchanged | Good practice; GL9 if the data are meant for FDA | Not the sole basis for effectiveness or target animal safety claims; may corroborate controlled studies and yield safety data (514.117(e)) |
| An approved product used as its label says, such as the comparator | Not needed for that product | GL9 if meant for FDA; GL9 1.9 counts an approved product used per label, or a placebo, as a control | The comparison arm |
| The peptide supplied, assigned or dosed under the protocol | Required before shipment (511.1(b)(4)) | GL9; the protocol states it follows a standard of conduct acceptable to FDA (514.117(b)(2)) | Evidence toward approval, when the field study uses an appropriate control and minimizes bias (514.117(c)(2)) |
A research-use-only label gives no directions for dogs, so there is no on-label use of the peptide to study. An observational study also shows the seller knows how the product is used, which is one of the circumstances 201.128 names.
What 511.1 asks
- The label reads "Caution. Contains a new animal drug for use only in investigational animals in clinical trials. Not for use in humans." (511.1(b)(1)).
- Before shipment, the sponsor submits a Notice of Claimed Investigational Exemption: the drug's identity, its labeling, each investigator's name and address, and the approximate number of animals (511.1(b)(4)).
- The shipper records each investigator's name and address and the date, quantity and batch or code mark of each shipment (511.1(b)(3)).
- Investigators are qualified by scientific training and/or experience, keep complete records including receipt and disposition of each shipment for 2 years after the investigation ends or the drug is approved, and report to the sponsor (511.1(b)(7)).
- The sponsor keeps investigator reports for 2 years, provides current monitoring by a qualified person, and promptly reports to FDA and all investigators any findings that may suggest significant hazards (511.1(b)(8)(i)–(ii)).
- The sponsor does not represent the drug as safe or effective for the purposes under investigation, and does not commercially distribute or test-market it until a new animal drug application is approved (511.1(b)(8)(iv)–(v)).
- Obligations handed to a contract research organization are transferred in writing (511.1(f)).
511.1 says nothing about owner consent or an ethics committee. CVM's draft Guidance #282 states that "there are no Federal laws that regulate the informed consent process" for these studies. For studies meant for FDA, GL9 supplies the duty: the investigator obtains informed consent from each owner before the animal takes part (3.2.13), and the monitor ensures it is obtained and recorded (5.2.8). GL9 also asks sponsor and investigator to comply with the requirements governing humane care of study animals (3.2.12, 4.2.17).
What the consent form should say
CVM recommends a consent form for every study with client-owned dogs, cats or horses, given to the owner at least 12 to 24 hours before enrollment where possible (#282, sections I and II). The guidance is a draft, so these are recommendations. Section VI asks the form to state:
- That the product is investigational, that its safety and effectiveness have not been demonstrated, and that the purpose is investigation rather than treatment, with nothing suggesting it is "safe" or "effective" (VI.A.1).
- The approximate number of dogs, the groups including any placebo, and the chance of being in the control group (VI.A.2).
- Alternatives, including approved drugs, and any treatment not allowed during the study (VI.A.3).
- The owner's duties, such as the diary, restrictions, when to call and visit dates, and any costs (VI.A.4, VI.A.5).
- Benefits without a guarantee, and any payment as compensation, not a benefit, never contingent on finishing (VI.B).
- That taking part is voluntary and the owner may withdraw without penalty (VI.C).
- Risks to the dog, and to people who handle the product or are exposed to it (VI.E).
- That significant new findings will be shared, and that FDA may inspect the records (VI.F, VI.G).
- A signature acknowledging the information and that the product is not FDA-approved for the use, with any agent's written authority attached (VI.H).
One recommendation matters to a company whose staff own dogs: avoid enrolling animals owned by investigators, employees or relatives of investigators or the sponsor, or anyone with an interest in the outcome (V.B).
The records
GL9 asks that raw data be attributable, original, accurate, contemporaneous and legible (8.3.1). When data go straight into a computer system, the electronic record is the raw data; each entry and change is made under the electronic signature of the person making it, and changes are kept in an audit trail (8.3.6). 21 CFR Part 11 applies to electronic records kept under any records requirement in FDA regulations (11.1(b)), and 511.1(b)(7)(ii) is one. GL9 excludes studies "not intended to be used for regulatory support" (2.6), but a pilot first kept without an audit trail cannot be given one afterwards.
What stays yours
The sponsor writes the protocol and signs it with the investigator (GL9 4.2.7), files the INAD notice, appoints the monitor, decides what the consent form says, arranges any ethics review, keeps the shipment records and reports hazards to FDA. The investigator obtains consent, records the data and accounts for every unit received. Both guidances encourage taking the protocol and the consent form to CVM before the study starts (GL9 6.2; #282 section VII). When a pet study needs an INAD covers the notice in more detail.
Signalment is a data system and does none of that. It holds the study's records: versioned protocol and consent, owner eConsent and an eDiary on the owner's phone, dosing and adverse event forms with the 21 CFR 514.3 serious criteria and ABON causality, randomization with concealed allocation, signatures that re-check the password and bind to the hash of what was signed, and an append-only, hash-chained audit trail a monitor can verify offline from the export. It has no drug accountability ledger yet, so the receipt and disposition records 511.1(b)(7)(ii) asks for are kept elsewhere for now, and it has no SAS or SEND export. More is on the sponsor page.
Sources
- 21 CFR 511.1, new animal drugs for investigational use: https://www.ecfr.gov/current/title-21/section-511.1
- 21 CFR 201.128, meaning of intended uses: https://www.ecfr.gov/current/title-21/section-201.128
- 21 CFR 530.1, scope of extralabel drug use in animals: https://www.ecfr.gov/current/title-21/section-530.1
- 21 CFR 514.117, adequate and well-controlled studies: https://www.ecfr.gov/current/title-21/section-514.117
- 21 CFR 11.1, scope of Part 11, electronic records and signatures: https://www.ecfr.gov/current/title-21/section-11.1
- FDA Guidance #85, VICH GL9, Good Clinical Practice: https://www.fda.gov/media/70333/download
- FDA Guidance #282 (draft, September 2023), Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals: https://www.fda.gov/media/172056/download
- FDA, Unapproved Animal Drugs: https://www.fda.gov/animal-veterinary/compliance-enforcement/unapproved-animal-drugs